Baseline Characteristics of Patients With Asthma and Prior Oral Systemic Corticosteroid Use Initiating Dupilumab in a Real-World Registry (RAPID)

DUPILUMAB

Njira L Lugogo[1], Enrico Heffler[2,3], Vicente Plaza[4], Ole Hilberg[5], Changming Xia[6], Scott Nash[6], Nami Pandit-Abid[7], Juby A Jacob-Nara[7], Harry Sacks[6], Paul J Rowe[7], Yamo Deniz[6], Megan Hardin[8], Casey Reed[8]*, Xavier Soler[6]

[1]University of Michigan, Ann Arbor, MI, USA; [2]IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy; [3]Humanitas University, Pieve Emanuele, Milan, Italy; [4]Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; [5]Lillebaelt Hospital, Vejle, Denmark; [6]Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA; [7]Sanofi, Bridgewater, NJ, USA; [8]Sanofi, Cambridge, MA, USA

Background

- Oral corticosteroid (OCS) use is a common therapeutic option for management of acute asthma exacerbations as well as chronic maintenance therapy for patients with severe disease[1]
- Dupilumab, a fully human monoclonal antibody,[2,3] blocks the shared receptor component for interleukin (IL)-4 and IL-13, which are key and central drivers of type 2 inflammation in multiple diseases[4,5]
- In previous dupilumab asthma studies (Phase 2b, QUEST, VENTURE, TRAVERSE), dupilumab significantly reduced the risk of severe asthma exacerbation, improved lung function, and reduced OCS use in the overall population of patients with uncontrolled, moderate-to-severe asthma[6–9]
- The Registry of Asthma Patients Initiating DUPIXENT® (RAPID; NCT04287621) is the first global, prospective, observational cohort of adolescent and adult patients with asthma initiating dupilumab treatment in a real-world setting

Methods

Study design

- RAPID enrolled patients aged ≥12 years with moderate-to-severe asthma initiating dupilumab treatment for a primary indication of asthma
- Eligible patients initiated dupilumab treatment for asthma according to country-specific prescribing information, per physician discretion, as part of routine care and will be followed prospectively for up to 3 years after treatment initiation
- This initial analysis of RAPID includes 205 patients who were enrolled between March 2020 and October 2021

Population

- Analysis population (N = 205)
- Patients with OCS use within 3 months prior to enrollment (n = 52)
- Patients without OCS use within 3 months prior to enrollment (n = 153)



Objective

- **To report baseline characteristics with focus on OCS use in patients enrolled in RAPID**

Conclusion

- **In this initial presentation of baseline characteristics of patients from RAPID initiating dupilumab for moderate-to-severe asthma, we show that 25.4% of patients were currently or had recently received OCS, indicating a high unmet need for optimized treatment in this population**

Results

Table 1. Baseline demographics of patients in the analysis population and in patients with and without a history of previous OCS use in the 3 months prior to enrollment in RAPID.

	Analysis population (N = 205)	Patients with previous OCS use (n = 52)	Patients without previous OCS use (n = 153)
Age, mean (SD), years	50.1 (17.4)	48.8 (16.8)	50.5 (17.7)
Female gender, n (%)	134 (65.4)	34 (65.4)	100 (65.4)
Race, n (%)			
White	152 (74.1)	35 (67.3)	117 (76.5)
Black or African American	27 (13.2)	8 (15.4)	19 (12.4)
Asian	2 (1.0)	0	2 (1.3)
Multiple	2 (1.0)	1 (1.9)	1 (0.7)
Other	6 (2.9)	3 (5.8)	3 (2.0)
Not reported	15 (7.3)	4 (7.7)	11 (7.2)
Missing	1 (0.5)	1 (1.9)	0
Ethnicity, n (%)			
Not Hispanic or Latino	162 (79.0)	41 (78.8)	121 (79.1)
Hispanic or Latino	35 (17.1)	9 (17.3)	26 (17.0)
Not reported	6 (2.9)	2 (3.8)	4 (2.6)
Unknown	2 (1.0)	0	2 (1.3)
Age at diagnosis of asthma, mean (SD), years	31.1 (21.9)	26.8 (21.8)	32.6 (21.8)
BMI, mean (SD), kg/m^2	30.67 (8.0)	31.65 (8.8)	30.33 (7.7)
Baseline BMI categories, n (%)			
<25	43 (21.0)	11 (21.2)	32 (20.9)
≥25 to <30	63 (30.7)	10 (19.2)	53 (34.6)
≥30	88 (42.9)	28 (53.8)	60 (39.2)
Missing	11 (5.4)	3 (5.8)	8 (5.2)

BMI, body mass index; SD, standard deviation.

Table 2. Baseline disease characteristics and patient-reported outcome scores of patients in the analysis population and in patients with and without a history of previous OCS use in the 3 months prior to enrollment in RAPID.

	Analysis population (N = 205)	Patients with previous OCS use (n = 52)	Patients without previous OCS use (n = 153)
Spirometry			
Pre-BD FEV_1, mean (SD), L	2.29 (1.1)	2.27 (1.5)	2.31 (0.9)
Pre-BD ppFEV_1, mean (SD), %	70.34 (20.3)	66.61 (21.4)	72.44 (19.5)
Pre-BD pp$FEF_{25–75\%}$, mean (SD), %	56.70 (29.2)	45.30 (26.7)	62.60 (29.0)
Pre-BD FVC, mean (SD), L	3.09 (1.1)	2.86 (1.1)	3.21 (1.1)
Pre-BD ppFVC, mean (SD), %	80.24 (19.0)	80.70 (20.3)	80.00 (18.5)
Pre-BD PEF, mean (SD), (L/min)	356.88 (169.8)	367.91 (203.6)	354.27 (162.9)
Eosinophils and FeNO			
Blood eosinophil count (Giga/L)			
Median (Q1–Q3)	0.305 (0.200–0.695)	0.252 (0.200–0.960)	0.310 (0.200–0.600)
Blood eosinophil count category, n/N1 (%)			
<150 cells/μL	10/64 (15.6)	3/15 (20.0)	7/49 (14.3)
≥150 to <300 cells/μL	15/64 (23.4)	5/15 (33.3)	10/49 (20.4)
≥300 cells/μL	39/64 (60.9)	7/15 (46.7)	32/49 (65.3)
FeNO, mean (SD), ppb	42.2 (34.8)	50.6 (34.8)	37.5 (34.4)
FeNO category, n/N1 (%)			
<25 ppb	22/61 (36.1)	5/22 (22.7)	17/39 (43.6)
≥25 ppb	39/61 (63.9)	17/22 (77.3)	22/39 (56.4)
PRO Scores			
ACQ-6, mean (SD)	2.36 (1.2)	2.77 (1.4)	2.21 (1.1)

ACQ-6, 6-item Asthma Control questionnaire; BD, bronchodilator; FEF, forced expiratory flow; $FEF_{25–75\%}$, forced expiratory flow at 25–75% of pulmonary volume; FeNO, fractional exhaled nitric oxide; FEV_1, forced expiratory volume in 1 second; FVC, forced vital capacity; L, liter; PEF, peak expiratory flow; pp, percent predicted; ppb, parts per billion; PRO, patient-related outcome; Q, quartile; SD, standard deviation.

Table 3. Baseline ICS asthma controller medications used by patients in the analysis population and in patients with and without a history of previous OCS use in the 3 months prior to enrollment in RAPID.

	Analysis population (N = 205)	Patients with previous OCS use (n = 52)	Patients without previous OCS use (n = 153)
ICS asthma controller medications, n (%)			
ICS	17 (8.3)	13 (25.0)	10 (6.5)
ICS + LABA	112 (54.6)	30 (57.7)	99 (64.7)
ICS + LABA + LAMA	23 (11.2)	10 (19.2)	16 (10.5)

ICS, inhaled corticosteroids; LABA, long-acting beta agonist; LAMA, long-acting muscarinic antagonist.

Table 4. Previous OCS medications used by patients with a history of previous OCS use in the 3 months prior to enrollment in RAPID.

	Patients with previous OCS use (n = 52)
Any previous OCS medications, n1 (%)	52 (100.0)
Ongoing[a], n/n1 (%)	21/52 (40.4)
Prednisone, n1 (%)	46 (88.5)
Ongoing, n/n1 (%)	19/46 (41.3)
Methylprednisolone, n1 (%)	2 (3.8)
Ongoing, n/n1 (%)	1/2 (50.0)
Methylprednisolone sodium succinate, n1 (%)	0 (0)
Ongoing, n/n1 (%)	0/0 (0)
Prednisolone, n1 (%)	3 (5.8)
Ongoing, n/n1 (%)	0/3 (0)
Dexamethasone, n1 (%)	1 (1.9)
Ongoing, n/n1 (%)	1/1 (100.0)
Betamethasone sodium phosphate, n1 (%)	0 (0)
Ongoing, n/n1 (%)	0/0 (0)
Hydrocortisone, n1 (%)	0 (0)
Ongoing, n/n1 (%)	0/0 (0)
Uncoded: methylprednisolone, n1 (%)	1 (1.9)
Ongoing, n/n1 (%)	0/1 (0)
Uncoded: prednisone, n1 (%)	0 (0)
Ongoing, n/n1 (%)	0/0 (0)

*Ongoing refers to medications used by patients enrolled in RAPID during a 6-month period.

References: 1. Global Strategy for Asthma Management and Prevention (2019 update). Available from: https://ginasthma.org/wp-content/uploads/2022/07/GINA-Main-Report-2022-FINAL-22-07-01-WMS.pdf. 2. Macdonald LE, et al. Proc Natl Acad Sci U S A. 2014;111:5147-52. 3. Murphy AJ, et al. Proc Natl Acad Sci U S A. 2014;111:5153-8. 4. Gandhi NA, et al. Expert Rev Clin Immunol. 2017;13:425-37. 5. Le Floc'h A, et al. Allergy 2020;75:1188-204. 6. Rabe KF, et al. N Engl J Med. 2018;378:2486-96. 7. Castro M, et al. N Engl J Med. 2018;378:2486-2496. 8. Wenzel S, et al. Lancet. 2016; 388:31-44. 9. Wechsler ME, et al. Lancet Respir Med. 2022;10:11-25.

Acknowledgments and funding sources: *Presenting on behalf of authors. Research sponsored by Sanofi and Regeneron Pharmaceuticals Inc. ClinicalTrials.gov Identifier: NCT04287621. Medical writing/editorial assistance was provided by Orthis Saha, PhD, of Excerpta Medica, and was funded by Sanofi and Regeneron Pharmaceuticals Inc., according to the Good Publication Practice guideline.

Disclosures: Lugogo NL: AstraZeneca, Genentech, GSK, Sanofi – clinical trial funding; AstraZeneca, Genentech, GSK, Novartis, Regeneron Pharmaceuticals Inc., Sanofi, Teva – advisory board member and consultant. **Heffler E:** AstraZeneca, Boehringer Ingelheim, Circassia, GSK, Nestlé Purina, Novartis, Sanofi, Teva, Valeas – research grants. **Plaza V:** AstraZeneca, Chiesi – clinical trial funding; AstraZeneca, Gebro Pharma, GSK, Novartis, Sanofi, Teva – advisory board member and consultant. **Hilberg O:** Sanofi – advisory boards. **Xia C, Nash S, Deniz Y, Soler X:** Regeneron Pharmaceuticals Inc. – employees and shareholders. **Sacks H:** Regeneron Pharmaceuticals Inc. – employee; Optinose Inc. – shareholder. **Pandit-Abid N, Jacob-Nara JA, Rowe PJ, Hardin M, Reed C:** Sanofi – employees, may hold stock and/or stock options in the company.

Presented at the 29th Annual Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR 2024); Atlanta, GA, USA, May 5-8, 2024.

Full poster download